The DOI matches its Crossref record; 115 of the 117 references it cites were found in a registry or an index.
Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Abstract
Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this context, the inhalation route is advantageous for the pulmonary delivery of anti-TB drugs and requires lower doses to achieve therapeutic effects. The pulmonary delivery of drugs is a convenient and effective approach for the treatment of TB.202”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [202]
Citations
Cites
Inhaling medicines: delivering drugs to the body through the lungs
Patton, J. S., & Byron, P. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2153 · Cited by 1,370
Xu, J., Kochanek, K. D., Murphy, S. L., & Tejada‐Vera, B. (2010) · PubMed · Cited by 650
The Lungs as a Portal of Entry for Systemic Drug Delivery
Patton, J. S., Fishburn, C. S., & Weers, J. G. (2004) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200409-049ta · Cited by 564
Nanomedicine in pulmonary delivery
Mansour, H. M., Haemosu, & Wu, X. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s4937 · Cited by 497
Self-citationOGILVIE, R. I. (1983) · PubMed Central · Cited by 395
Nanoparticle formulations in pulmonary drug delivery
Bailey, M. M., & Berkland, C. J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20140 · Cited by 302
Rijnders, B. J. A., Cornelissen, J. J., Slobbe, L., Becker, M. J., Doorduijn, J. K., Hop, W. C. J., Ruijgrok, E. J., Löwenberg, B., Vulto, A. G., Lugtenburg, P. J., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/586739 · Cited by 284
Zakharian, T. Y., Seryshev, A. B., Sitharaman, B., Gilbert, B. E., Knight, V., & Wilson, L. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0546525 · Cited by 277
Heijerman, H. G. M., Westerman, E. M., Conway, S., & Touw, D. J. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Nanomedicine for respiratory diseases
Pison, U., Welte, T., Giersig, M., & Groneberg, D. A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.068 · Cited by 262
Research works printed but not linked: 4
- Hickey AJ, Mansour HM (2009) Chapter 5: delivery of drugs by the pulmonary route. In: Florence AT, Siepmann J (eds) Modern pharmaceutics, vol 2, 5th edn. Taylor and Francis, New York, pp 191–219
- Perrie Y, Rades T (2010) Pharmaceutics—drug delivery and targeting. Pharmaceutical Press, London
- Darwis Y, Kellaway IW (2002) The lyophilisation and aerosolisation of liposomes for pulmonary drug administration. STP Pharma Sci 12(2):91–96
- DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (2008) Pharmacotherapy: a pathophysiological approach, 7th edn. McGraw-Hill Medical, New York
Cited by
Sorted by citations
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Nanoparticle-Mediated Pulmonary Drug Delivery: A Review
Paranjpe, M., & Müller-Goymann, C. C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045852 · Cited by 467
Delivery strategies for sustained drug release in the lungs
Loira-Pastoriza, C., Todoroff, J., & Rita Vanbever, A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.017 · Cited by 395
Nanotechnology approaches for inhalation treatment of lung diseases
Kuzmov, A., & Minko, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.024 · Cited by 356
Technological and practical challenges of dry powder inhalers and formulations
Hoppentocht, M., Hagedoorn, P., Frijlink, H. W., & de Boer, A. H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.04.004 · Cited by 304
Metadata
- Authors
- Willis, L., Hayes, D., & Mansour, H. M.
- Affiliations
- University of Kentucky (US)
- Nationwide Children's Hospital (US)
- Corresponding author
- Mansour, Heidi M.
- Venue
- Lung
- Published
- 2012-01-25
- Volume
- 190
- Issue
- 3
- Pages
- 251-262
- ISSN
- 0341-2040 (ISSN-L)
- 1432-1750
- OpenAlex
- W2081617033
- Cited by
- 148
- References
- 117
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 10 · 2023: 12 · 2022: 11 · 2021: 7 · 2020: 14 · 2019: 8 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 8 · 2014: 22 · 2013: 11 · 2012: 2
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Lung (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- lipospheres, proliposomes, dry powder inhaler, phospholipids, pulmonary surfactant, controlled drug release, formulation stability, lung disease, lung cancer, tuberculosis, cystic fibrosis, chronic obstructive pulmonary disease, asthma, pulmonary infection
- MeSH terms
- Administration, Inhalation, Aerosols, Pharmaceutical Preparations, Humans, Liposomes, Lung, Lung Diseases, Powders, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
